PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35269785-3	2022	Previously, we showed that the phenolic compounds corilagin and 1,3,6-tri-O-galloyl-beta-D-glucose (TGG) inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 target receptor on the cell membrane of the host organism.	corilagin	50-59	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	152-157	
34029937-15	2021	Our findings suggest that corilagin could be a safe and potential antiviral agent against the COVID-19 acting through the blockade of the fusion of SARS-CoV-2 spike-RBD to hACE2 receptors.	corilagin	26-35	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	159-164